The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pulmonary Drug Delivery Systems Market Research Report 2025
Synopsis
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
The global Pulmonary Drug Delivery Systems market was valued at US$ 3046.1 million in 2023 and is anticipated to reach US$ 4076.7 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
The major players in global Pulmonary Drug Delivery Systems market include 3M, GSK, AstraZeneca, etc. The top 3 players occupy about 60% shares of the global market. Europe and North America are main markets, they occupy over 75% of the global market. Metered Dose Inhaler (MDI) is the main type, with a share over 60%. COPD is the main application, which holds a share over 50%.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Drug Delivery Systems.
Report Scope
The Pulmonary Drug Delivery Systems market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pulmonary Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Drug Delivery Systems manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
Segment by Type
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
Segment by Application
COPD
Asthma
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pulmonary Drug Delivery Systems manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pulmonary Drug Delivery Systems in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
The global Pulmonary Drug Delivery Systems market was valued at US$ 3046.1 million in 2023 and is anticipated to reach US$ 4076.7 million by 2030, witnessing a CAGR of 4.2% during the forecast period 2024-2030.
The major players in global Pulmonary Drug Delivery Systems market include 3M, GSK, AstraZeneca, etc. The top 3 players occupy about 60% shares of the global market. Europe and North America are main markets, they occupy over 75% of the global market. Metered Dose Inhaler (MDI) is the main type, with a share over 60%. COPD is the main application, which holds a share over 50%.
This report aims to provide a comprehensive presentation of the global market for Pulmonary Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pulmonary Drug Delivery Systems.
Report Scope
The Pulmonary Drug Delivery Systems market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pulmonary Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pulmonary Drug Delivery Systems manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
Segment by Type
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
Segment by Application
COPD
Asthma
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pulmonary Drug Delivery Systems manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pulmonary Drug Delivery Systems in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pulmonary Drug Delivery Systems Market Overview
1.1 Product Overview and Scope of Pulmonary Drug Delivery Systems
1.2 Pulmonary Drug Delivery Systems Segment by Type
1.2.1 Global Pulmonary Drug Delivery Systems Market Value Comparison by Type (2024-2030)
1.2.2 Nebulizers
1.2.3 Dry Powder Inhaler (DPI)
1.2.4 Metered Dose Inhaler (MDI)
1.3 Pulmonary Drug Delivery Systems Segment by Application
1.3.1 Global Pulmonary Drug Delivery Systems Market Value by Application: (2024-2030)
1.3.2 COPD
1.3.3 Asthma
1.3.4 Others
1.4 Global Pulmonary Drug Delivery Systems Market Size Estimates and Forecasts
1.4.1 Global Pulmonary Drug Delivery Systems Revenue 2019-2030
1.4.2 Global Pulmonary Drug Delivery Systems Sales 2019-2030
1.4.3 Global Pulmonary Drug Delivery Systems Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pulmonary Drug Delivery Systems Market Competition by Manufacturers
2.1 Global Pulmonary Drug Delivery Systems Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pulmonary Drug Delivery Systems Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pulmonary Drug Delivery Systems Average Price by Manufacturers (2019-2024)
2.4 Global Pulmonary Drug Delivery Systems Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pulmonary Drug Delivery Systems, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pulmonary Drug Delivery Systems, Product Type & Application
2.7 Pulmonary Drug Delivery Systems Market Competitive Situation and Trends
2.7.1 Pulmonary Drug Delivery Systems Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pulmonary Drug Delivery Systems Players Market Share by Revenue
2.7.3 Global Pulmonary Drug Delivery Systems Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pulmonary Drug Delivery Systems Retrospective Market Scenario by Region
3.1 Global Pulmonary Drug Delivery Systems Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pulmonary Drug Delivery Systems Global Pulmonary Drug Delivery Systems Sales by Region: 2019-2030
3.2.1 Global Pulmonary Drug Delivery Systems Sales by Region: 2019-2024
3.2.2 Global Pulmonary Drug Delivery Systems Sales by Region: 2025-2030
3.3 Global Pulmonary Drug Delivery Systems Global Pulmonary Drug Delivery Systems Revenue by Region: 2019-2030
3.3.1 Global Pulmonary Drug Delivery Systems Revenue by Region: 2019-2024
3.3.2 Global Pulmonary Drug Delivery Systems Revenue by Region: 2025-2030
3.4 North America Pulmonary Drug Delivery Systems Market Facts & Figures by Country
3.4.1 North America Pulmonary Drug Delivery Systems Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
3.4.3 North America Pulmonary Drug Delivery Systems Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pulmonary Drug Delivery Systems Market Facts & Figures by Country
3.5.1 Europe Pulmonary Drug Delivery Systems Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
3.5.3 Europe Pulmonary Drug Delivery Systems Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pulmonary Drug Delivery Systems Market Facts & Figures by Country
3.6.1 Asia Pacific Pulmonary Drug Delivery Systems Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
3.6.3 Asia Pacific Pulmonary Drug Delivery Systems Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Pulmonary Drug Delivery Systems Market Facts & Figures by Country
3.7.1 Latin America Pulmonary Drug Delivery Systems Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
3.7.3 Latin America Pulmonary Drug Delivery Systems Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pulmonary Drug Delivery Systems Market Facts & Figures by Country
3.8.1 Middle East and Africa Pulmonary Drug Delivery Systems Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pulmonary Drug Delivery Systems Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pulmonary Drug Delivery Systems Sales by Type (2019-2030)
4.1.1 Global Pulmonary Drug Delivery Systems Sales by Type (2019-2024)
4.1.2 Global Pulmonary Drug Delivery Systems Sales by Type (2025-2030)
4.1.3 Global Pulmonary Drug Delivery Systems Sales Market Share by Type (2019-2030)
4.2 Global Pulmonary Drug Delivery Systems Revenue by Type (2019-2030)
4.2.1 Global Pulmonary Drug Delivery Systems Revenue by Type (2019-2024)
4.2.2 Global Pulmonary Drug Delivery Systems Revenue by Type (2025-2030)
4.2.3 Global Pulmonary Drug Delivery Systems Revenue Market Share by Type (2019-2030)
4.3 Global Pulmonary Drug Delivery Systems Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pulmonary Drug Delivery Systems Sales by Application (2019-2030)
5.1.1 Global Pulmonary Drug Delivery Systems Sales by Application (2019-2024)
5.1.2 Global Pulmonary Drug Delivery Systems Sales by Application (2025-2030)
5.1.3 Global Pulmonary Drug Delivery Systems Sales Market Share by Application (2019-2030)
5.2 Global Pulmonary Drug Delivery Systems Revenue by Application (2019-2030)
5.2.1 Global Pulmonary Drug Delivery Systems Revenue by Application (2019-2024)
5.2.2 Global Pulmonary Drug Delivery Systems Revenue by Application (2025-2030)
5.2.3 Global Pulmonary Drug Delivery Systems Revenue Market Share by Application (2019-2030)
5.3 Global Pulmonary Drug Delivery Systems Price by Application (2019-2030)
6 Key Companies Profiled
6.1 3M
6.1.1 3M Corporation Information
6.1.2 3M Description and Business Overview
6.1.3 3M Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.1.4 3M Pulmonary Drug Delivery Systems Product Portfolio
6.1.5 3M Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GSK Pulmonary Drug Delivery Systems Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Corporation Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.3.4 AstraZeneca Pulmonary Drug Delivery Systems Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Cipla
6.4.1 Cipla Corporation Information
6.4.2 Cipla Description and Business Overview
6.4.3 Cipla Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Cipla Pulmonary Drug Delivery Systems Product Portfolio
6.4.5 Cipla Recent Developments/Updates
6.5 Chiesi
6.5.1 Chiesi Corporation Information
6.5.2 Chiesi Description and Business Overview
6.5.3 Chiesi Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Chiesi Pulmonary Drug Delivery Systems Product Portfolio
6.5.5 Chiesi Recent Developments/Updates
6.6 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Boehringer Ingelheim Pulmonary Drug Delivery Systems Product Portfolio
6.6.5 Boehringer Ingelheim Recent Developments/Updates
6.7 Aptar
6.6.1 Aptar Corporation Information
6.6.2 Aptar Description and Business Overview
6.6.3 Aptar Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Aptar Pulmonary Drug Delivery Systems Product Portfolio
6.7.5 Aptar Recent Developments/Updates
6.8 Novartis
6.8.1 Novartis Corporation Information
6.8.2 Novartis Description and Business Overview
6.8.3 Novartis Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Novartis Pulmonary Drug Delivery Systems Product Portfolio
6.8.5 Novartis Recent Developments/Updates
6.9 Philips Respironics
6.9.1 Philips Respironics Corporation Information
6.9.2 Philips Respironics Description and Business Overview
6.9.3 Philips Respironics Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Philips Respironics Pulmonary Drug Delivery Systems Product Portfolio
6.9.5 Philips Respironics Recent Developments/Updates
6.10 Omron Healthcare
6.10.1 Omron Healthcare Corporation Information
6.10.2 Omron Healthcare Description and Business Overview
6.10.3 Omron Healthcare Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Omron Healthcare Pulmonary Drug Delivery Systems Product Portfolio
6.10.5 Omron Healthcare Recent Developments/Updates
6.11 PARI
6.11.1 PARI Corporation Information
6.11.2 PARI Pulmonary Drug Delivery Systems Description and Business Overview
6.11.3 PARI Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.11.4 PARI Pulmonary Drug Delivery Systems Product Portfolio
6.11.5 PARI Recent Developments/Updates
6.12 Skyepharma
6.12.1 Skyepharma Corporation Information
6.12.2 Skyepharma Pulmonary Drug Delivery Systems Description and Business Overview
6.12.3 Skyepharma Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Skyepharma Pulmonary Drug Delivery Systems Product Portfolio
6.12.5 Skyepharma Recent Developments/Updates
6.13 CareFusion
6.13.1 CareFusion Corporation Information
6.13.2 CareFusion Pulmonary Drug Delivery Systems Description and Business Overview
6.13.3 CareFusion Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.13.4 CareFusion Pulmonary Drug Delivery Systems Product Portfolio
6.13.5 CareFusion Recent Developments/Updates
6.14 Shanghai Huarui
6.14.1 Shanghai Huarui Corporation Information
6.14.2 Shanghai Huarui Pulmonary Drug Delivery Systems Description and Business Overview
6.14.3 Shanghai Huarui Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Shanghai Huarui Pulmonary Drug Delivery Systems Product Portfolio
6.14.5 Shanghai Huarui Recent Developments/Updates
6.15 Taian Character
6.15.1 Taian Character Corporation Information
6.15.2 Taian Character Pulmonary Drug Delivery Systems Description and Business Overview
6.15.3 Taian Character Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Taian Character Pulmonary Drug Delivery Systems Product Portfolio
6.15.5 Taian Character Recent Developments/Updates
6.16 Chia Tai Tianqing
6.16.1 Chia Tai Tianqing Corporation Information
6.16.2 Chia Tai Tianqing Pulmonary Drug Delivery Systems Description and Business Overview
6.16.3 Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Chia Tai Tianqing Pulmonary Drug Delivery Systems Product Portfolio
6.16.5 Chia Tai Tianqing Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pulmonary Drug Delivery Systems Industry Chain Analysis
7.2 Pulmonary Drug Delivery Systems Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pulmonary Drug Delivery Systems Production Mode & Process
7.4 Pulmonary Drug Delivery Systems Sales and Marketing
7.4.1 Pulmonary Drug Delivery Systems Sales Channels
7.4.2 Pulmonary Drug Delivery Systems Distributors
7.5 Pulmonary Drug Delivery Systems Customers
8 Pulmonary Drug Delivery Systems Market Dynamics
8.1 Pulmonary Drug Delivery Systems Industry Trends
8.2 Pulmonary Drug Delivery Systems Market Drivers
8.3 Pulmonary Drug Delivery Systems Market Challenges
8.4 Pulmonary Drug Delivery Systems Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
